Betacellulin drives therapy resistance in glioblastoma
نویسندگان
چکیده
منابع مشابه
Sprouty2 Drives Drug Resistance and Proliferation in Glioblastoma.
UNLABELLED Glioblastoma multiforme (GBM) is notoriously resistant to therapy, and the development of a durable cure will require the identification of broadly relevant regulators of GBM cell tumorigenicity and survival. Here, we identify Sprouty2 (SPRY2), a known regulator of receptor tyrosine kinases (RTK), as one such regulator. SPRY2 knockdown reduced proliferation and anchorage-independent ...
متن کاملGlioblastoma Multiforme Therapy and Mechanisms of Resistance
Glioblastoma multiforme (GBM) is a grade IV brain tumor characterized by a heterogeneous population of cells that are highly infiltrative, angiogenic and resistant to chemotherapy. The current standard of care, comprised of surgical resection followed by radiation and the chemotherapeutic agent temozolomide, only provides patients with a 12-14 month survival period post-diagnosis. Long-term sur...
متن کاملc-Myc-miR-29c-REV3L signalling pathway drives the acquisition of temozolomide resistance in glioblastoma.
Resistance to temozolomide poses a major clinical challenge in glioblastoma multiforme treatment, and the mechanisms underlying the development of temozolomide resistance remain poorly understood. Enhanced DNA repair and mutagenesis can allow tumour cells to survive, contributing to resistance and tumour recurrence. Here, using recurrent temozolomide-refractory glioblastoma specimens, temozolom...
متن کاملMetabolic rewiring drives resistance to targeted cancer therapy
Cancers are diseases of uncontrolled cell growth in which cells acquire mutations that allow for proliferation outside the context of normal tissue development. The genetic events that define tumorigenesis have been, to a large extent, cataloged (Stratton et al, 2009; Beroukhim et al, 2010). Therapies have been developed that interfere with these defined genetic aberrations (Slamon et al, 1989)...
متن کاملA Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma.
Although signaling from phosphatidylinositol 3-kinase (PI3K) and AKT to mechanistic target of rapamycin (mTOR) is prominently dysregulated in high-grade glial brain tumors, blockade of PI3K or AKT minimally affects downstream mTOR activity in glioma. Allosteric mTOR inhibitors, such as rapamycin, incompletely block mTORC1 compared with mTOR kinase inhibitors (TORKi). Here, we compared RapaLink-...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neuro-Oncology
سال: 2019
ISSN: 1522-8517,1523-5866
DOI: 10.1093/neuonc/noz206